Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK
Conditions
Triple-negative Breast Cancer · TNBC - Triple-Negative Breast Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Tumor Zentrum Aarau, Aarau, Switzerland
St. Claraspital, Basel, Switzerland
Contact: Study coordinator (Corinne Cescato, MD) · Corinne.Cescato-Wenger@claraspital.ch · +41 61 685 83 67Contact: Principal Investigator (Thomas Schmid, MD)EOC - IOSI Ospedale regionale Bellinzona e valli - San Giovanni, Bellinzona, Switzerland
Contact: Principal Investigator (Lorenzo Rossi, MD)Kantonsspital Graubünden, Chur, Switzerland
Contact: Principal Investigator (Michael Schwitter, MD)Kantonsspital Baselland, Liestal, Switzerland
Contact: Principal Investigator (Marcus Vetter, MD)HOCH Health Ostschweiz, Sankt Gallen, Switzerland
Contact: Principal Investigator (Markus Jörger, MD)TBZO - Tumor- & Brustzentrum Ostschweiz, Sankt Gallen, Switzerland
Kantonsspital Winterthur, Winterthur, Switzerland
Contact: Principal Investigator (Ursina Zürrer, MD)Universitätsspital Zürich - Klinik für Gynäkologie, Zurich, Switzerland
Contact: Principal Investigator (Isabell Witzel, Prof)
Study leads
Markus Joerger, Prof
Study Director
HOCH Health Ostschweiz - Kantonsspital St. Gallen
Ursina Zürrer, MD
Study Chair
Kantonsspital Winterthur KSW